The day at a glance · 3 min read
Mood · Cautious
+15
Sentiment, −100 to +100
State Street Health Care SPDR sales
$300.3M
AbbVie ETF net selling
$62.0M
XLV assets under management
$50.56B
Key driverLarge ETF selling pressure on major pharma names offset by institutional buying in biotech and continued medical device adoption gains
Daily briefHealthcare· Money365.Market AI ·

Healthcare Sector Sees Mixed Flows; Tech Push Expands

Major ETFs trim pharma holdings while Flagship opens London AI lab; Intuitive da Vinci 5 installed base crosses 2,000 units

Healthcare Market Overview

Bearish
01XLV
The healthcare sector experienced significant ETF outflows last week as State Street Health Care SPDR common stock ETF (XLV) sold $300.3 million of stock on November 12, cutting all 60 positions and adding nothing, while its assets under management stood at $50.56 billion.
02ABBV
AbbVie (ABBV) common stock faced net selling pressure of $62.0 million from ETFs, with 40 funds buying and 16 selling. The flows reflected a broader rotation as institutional investors adjusted allocations across large-cap pharma and biotech names entering the final weeks of the year.

Big Pharma & Biotech

Bullish

BlackRock/Vanguard biotech share purchases

8.12M

Flagship UK lab initial commitment

£100M
LLYMRNA
01LLY▲ +1.14%
Eli Lilly (LLY) common stock and Merck were among the names added by BlackRock and Vanguard Capital Management in Q3, alongside smaller biotech names SLS, IBRX, and IOVA, with the two asset managers accumulating 8.12 million shares across the three biotech positions.
02MRNA▼ -3.45%
Flagship Pioneering, the innovation engine behind Moderna (MRNA) common stock, announced the establishment of Flagship Origination Lab U.K., its first dedicated company creation unit outside the United States, based in London and focused on conceiving, testing, funding, and building AI-native platform companies that advance human and planetary health. Flagship committed an initial £100 million to launch the lab, which will operate as part of its broader scientific innovation infrastructure.
03
Karo Healthcare appointed Sue Egstrand as Chief Executive Officer to lead the next phase of growth toward becoming a top five consumer healthcare player in Europe, with Egstrand assuming her role on January 1, 2027.

MedTech & Devices

Bullish

da Vinci 5 installed base

2,000
01ISRG
Intuitive Surgical (ISRG) common stock reported that its da Vinci 5 installed base has surpassed 2,000 units, marking a significant milestone in the adoption of its newest surgical robotics platform. The installed base expansion demonstrates continued commercial traction for the fifth-generation system as hospitals and surgical centers upgrade capital equipment to access advanced capabilities in minimally invasive surgery. The company's growth trajectory positions it for continued market share gains in robotic-assisted procedures over the next decade as the technology becomes standard of care across a broader range of surgical specialties.

Looking Ahead

Neutral
01AMGN
Investor attention remains focused on upcoming ex-dividend dates for large-cap pharma and biotech names, with Amgen (AMGN) common stock among four Nasdaq dividend payers hitting ex-dividend dates within the next two trading days. The London-based Flagship Origination Lab will begin operations in early 2027, adding a new geographic hub for AI-driven drug discovery and platform company creation outside the United States. Institutional positioning shifts will continue to influence sector flows as asset managers finalize year-end portfolio allocations across pharma, biotech, and medical device exposures.

Important Disclaimer — Not Investment Advice

Disclaimer: This article is provided by Money365.Market for general information and educational purposes only. It is not financial advice, a personal recommendation, or an inducement to buy, sell, or invest in any security or product. Capital is at risk and the value of investments can go down as well as up; past performance does not indicate future results. You should seek independent advice from an FCA-authorised adviser before making any financial decision.

Read the full disclaimer — 8 further points, including total-loss risk, our regulatory status and conflicts of interest

Nothing here is an offer or a solicitation to buy or sell anything, and reading it creates no advisory or fiduciary relationship between you and Money365.Market. Any decision you take is your own.

  • You can lose money — including all of it. Individual companies can and do fail, and some of the assets discussed can fall to zero. Only commit money you can afford to lose, and never borrow to invest on the strength of anything you read here.
  • Forecasts are opinion, not fact. Any valuation model, scenario, fair-value range, estimate or other forward-looking statement is illustrative, rests on assumptions that may prove wrong, and is never a price target, a forecast of actual outcomes, or a promise of any return.
  • Published at a point in time. Figures were believed accurate on the publication or last-updated date shown above and are not maintained afterwards; we are under no obligation to update them. Market and company data comes from third-party sources and is provided without warranty of accuracy, completeness or timeliness.
  • Automated content. This brief was compiled by an automated pipeline from validated news and market-data sources and passed through editorial and compliance checks. Automated content can still contain errors — verify anything you intend to rely on.
  • We are not regulated. Money365.Market is not authorised or regulated by the UK Financial Conduct Authority, is not registered with the U.S. Securities and Exchange Commission or FINRA as an investment adviser or broker-dealer, and is not a tax adviser. We hold no licence to give personal financial advice and do not do so.
  • Interests and independence. Money365.Market is not affiliated with, endorsed by or sponsored by any company, fund, exchange or platform mentioned, and is not paid to feature them. The author may hold positions in securities or assets discussed. The site earns revenue from advertising, subscriptions and, where labelled, affiliate links; this does not influence what we publish.
  • Your jurisdiction matters. Tax treatment, contribution limits, product availability and investor protections differ by country and can change. Speak to a qualified tax professional for tax matters, and to a locally licensed adviser if you are outside the UK.

Full terms: Disclaimer · Terms of Service · Privacy Policy